Contributors |
|
xi | |
Preface |
|
xiii | |
Foreword |
|
xvii | |
|
1 Definitions, Standard of Care and Ethical Considerations |
|
|
1 | (18) |
|
|
|
1 | (1) |
|
|
1 | (9) |
|
Guidelines for Ethical Practice and Liability Protection |
|
|
10 | (4) |
|
|
14 | (5) |
|
2 An Introductory Perspective on the Emerging Application of qEEG in Neurofeedback |
|
|
19 | (36) |
|
|
|
20 | (2) |
|
Concerns Regarding Normative Databases |
|
|
22 | (1) |
|
Other Factors Affecting Data |
|
|
23 | (2) |
|
Additional Analysis Methods |
|
|
25 | (1) |
|
|
25 | (1) |
|
|
26 | (3) |
|
Artifacts and Challenges to Collecting Data |
|
|
29 | (1) |
|
|
30 | (1) |
|
The Cortical Window and Default Mode |
|
|
30 | (5) |
|
Connecting Frequency Function to Location Function by Symptom |
|
|
35 | (4) |
|
|
39 | (1) |
|
|
40 | (1) |
|
|
41 | (1) |
|
|
42 | (2) |
|
|
44 | (1) |
|
|
44 | (1) |
|
Approaches to Reading a qEEG Map |
|
|
45 | (2) |
|
|
47 | (2) |
|
|
49 | (1) |
|
|
50 | (5) |
|
3 Neurofeedback and Psychopharmacology |
|
|
55 | (30) |
|
|
|
|
56 | (1) |
|
|
57 | (5) |
|
|
62 | (2) |
|
|
64 | (5) |
|
|
69 | (4) |
|
|
73 | (3) |
|
|
76 | (3) |
|
|
79 | (6) |
|
4 Hidden Factors Thwarting Success |
|
|
85 | (42) |
|
|
Thinking About the Field of Treatment |
|
|
85 | (4) |
|
The Sociotechnical Soiree: Sentient, Physical, Technical and Boundary Forces Within and Between Patient and Therapist |
|
|
89 | (13) |
|
ADD/ADHD as the Great Concealer |
|
|
102 | (8) |
|
The Family as a Hidden Factor |
|
|
110 | (9) |
|
Methodology as a Hidden Factor: Good Clinical Hygiene |
|
|
119 | (3) |
|
|
122 | (1) |
|
|
122 | (5) |
|
5 Defining Developing Evidence-Based Medicine Databases Proving Treatment Efficacy |
|
|
127 | (12) |
|
|
|
137 | (2) |
|
6 Treating Attention Deficits and Impulse Control |
|
|
139 | (32) |
|
|
|
139 | (1) |
|
A Case Report of Neurofeedback Treatment |
|
|
140 | (1) |
|
|
141 | (2) |
|
Medication in ADHD: Treatment Through Dopamine and Norepinephrine |
|
|
143 | (1) |
|
Nonmedication Neuromodulation as a Treatment Method for ADHD: Different Approaches to the Same Disorder |
|
|
144 | (9) |
|
General Comments Concerning Research on Neuromodulation Techniques with ADHD |
|
|
153 | (2) |
|
|
155 | (7) |
|
Methods of Neurofeedback and the Framework of Attention |
|
|
162 | (3) |
|
|
165 | (1) |
|
|
166 | (5) |
|
7 Treating Mood Disorders |
|
|
171 | (20) |
|
|
Neurofeedback for Depression |
|
|
172 | (4) |
|
Auditory--Visual Stimulation |
|
|
176 | (4) |
|
Cranial Electrostimulation |
|
|
180 | (2) |
|
Transcranial Magnetic Stimulation |
|
|
182 | (2) |
|
|
184 | (1) |
|
|
185 | (1) |
|
|
186 | (5) |
|
8 Diagnosing and Treating Closed Head Injury |
|
|
191 | (22) |
|
|
|
191 | (1) |
|
|
192 | (1) |
|
|
193 | (1) |
|
|
194 | (1) |
|
Electroencephalography (EEG) |
|
|
194 | (2) |
|
Diagnosis of MTBI with EEG |
|
|
196 | (3) |
|
Treating the "Silent Epidemic" |
|
|
199 | (1) |
|
|
199 | (3) |
|
Transcranial Stimulation Tools |
|
|
202 | (1) |
|
|
203 | (1) |
|
|
203 | (2) |
|
|
205 | (1) |
|
|
205 | (8) |
|
9 Treating Thought Disorders |
|
|
213 | (40) |
|
|
Thought Disorders, Psychosis |
|
|
213 | (2) |
|
qEEG, Neuroimaging Studies, VARETA, LORETA |
|
|
215 | (5) |
|
Psychopharmacological Treatment |
|
|
220 | (1) |
|
Scientific Evidence of Nonmedication Treatment Models in Psychosis |
|
|
221 | (16) |
|
|
237 | (2) |
|
|
239 | (14) |
|
10 Treating Chronic Pain Disorders |
|
|
253 | (12) |
|
|
|
|
260 | (5) |
|
11 Treating Addiction Disorders |
|
|
265 | (36) |
|
|
|
|
|
265 | (1) |
|
Studies of EEG Biofeedback in Substance Abuse Treatment |
|
|
266 | (6) |
|
Integrating Neurotherapy with Other Therapies |
|
|
272 | (8) |
|
Rationale for Neurofeedback Application in Adolescent Substance Abusers with Comorbid Disruptive Behavioral Disorders |
|
|
280 | (3) |
|
Treatment Strategies for ADHD and Substance Abuse in Adolescents |
|
|
283 | (3) |
|
Neurofeedback-Based Intervention in Drug-Abusing Adolescents with ADHD |
|
|
286 | (1) |
|
|
287 | (2) |
|
|
289 | (12) |
|
12 Neurofeedback for Seizure Disorders |
|
|
301 | (20) |
|
|
|
Origins of Neurofeedback in the Treatment of Seizure Disorders |
|
|
302 | (3) |
|
|
305 | (7) |
|
|
312 | (3) |
|
|
315 | (3) |
|
|
318 | (3) |
|
13 Diagnosing and Treating Developmental Disorders with qEEG and Neurotherapy |
|
|
321 | (36) |
|
|
|
321 | (2) |
|
The Role of qEEG in the Description and Classification of Developmental Disorders |
|
|
323 | (1) |
|
Single-Site Training and Emerging Neuroscientific Findings About Neural Networks |
|
|
324 | (1) |
|
Special Considerations of qEEG Assessment and Persons with Developmental Disorders |
|
|
325 | (4) |
|
General Considerations in Treatment Planning and Treatment for Developmental Disorders |
|
|
329 | (4) |
|
Principles of Planning Neurofeedback Treatment of Developmental Disorders |
|
|
333 | (1) |
|
Research on Neurofeedback Treatment of Specific Developmental Disabilities |
|
|
334 | (16) |
|
|
350 | (2) |
|
|
352 | (5) |
|
14 Nutrition for ADHD and Autism |
|
|
357 | (26) |
|
|
Nutrigenomics, Epigenetics, Nutrients and Lifestyle |
|
|
357 | (2) |
|
Omega-3 (n-3) and Omega-6 (n-6) Essential Fatty Acid (EFA) balance |
|
|
359 | (12) |
|
Zinc as an Essential Nutrient for Health |
|
|
371 | (4) |
|
|
375 | (2) |
|
Evidence-Based Prescribing of Nutrients |
|
|
377 | (1) |
|
|
378 | (5) |
|
15 Vision Therapy as a Complementary Procedure During Neurotherapy |
|
|
383 | (14) |
|
|
|
383 | (2) |
|
|
385 | (5) |
|
|
390 | (1) |
|
|
391 | (1) |
|
Suggestions for Clinical Practice |
|
|
392 | (3) |
|
|
395 | (2) |
|
|
397 | (16) |
|
|
|
397 | (1) |
|
Classification of Neurotherapy Systems |
|
|
398 | (4) |
|
Individualized Assessment and Treatment |
|
|
402 | (2) |
|
Integration and Ease of Use |
|
|
404 | (3) |
|
Localization and Connectivity-Based Methods |
|
|
407 | (2) |
|
|
409 | (1) |
|
External Factors Affecting Neurotherapy |
|
|
410 | (2) |
|
|
412 | (1) |
Index |
|
413 | |